Drug Trial Radar · NCT03811912
Efficacy and Tolerability Study of Two Dose Regimens of CTP-543 in Adults With Alopecia Areata
Last checked: Nov 19, 2026Latest source record: Dec 9, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
57
Actual
Start
Mar 21, 2019
Primary completion
Nov 21, 2019
Study completion Nov 21, 2019
Sponsor
- Lead sponsor
- Concert PharmaceuticalsIndustry
- Sponsor type
- Industry
- First posted
- Jan 22, 2019
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will evaluate the efficacy and tolerability of once-daily versus twice-daily dosing of CTP-543, in adult patients with chronic, moderate to severe alopecia areata.
Conditions
- Alopecia Areata
Interventions
CTP-543Drug
CTP-543 administered as 8 mg tablet.
CTP-543 Matching PlaceboDrug
Administered as tablets to aid treatment masking.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Relative Change From Baseline in Severity of Alopecia Tool (SALT) Score at Week 24Time frame: Baseline, Week 24
Locations
10 sites in 1 country. Site status is shown where the registry gives one.
Investigative Site
Irvine, California
Investigative Site
San Francisco, California
Investigative Site
New Haven, Connecticut
Investigative Site
Boynton Beach, Florida
Investigative Site
Boston, Massachusetts
Investigative Site
Boston, Massachusetts
Investigative Site
Fridley, Minnesota
Investigative Site
Portsmouth, New Hampshire
Investigative Site
Winston-Salem, North Carolina
Investigative Site
Portland, Oregon
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.